In vitro study of the effect of doxorubicin released from EVAL membrane on vesical cancer cells
Source abstract
Abstract
A mixture of poly(ethylene-co-vinyl alcohol) (EVAL), dimethyl sulfoxide (DMSO) and doxorubicin was precipitated from the 1-octanol to form membranes with particles bonded to each other. The drug release profile from the EVAL membrane was investigated for 96 h. Results showed that the release behavior of doxorubicin was increasing with time and a two-step release behavior, a fast and a slow releasing pattern was revealed. It was also found that the number of cancer cells could be significantly decreased by released doxorubicin from the EVAL membrane. It is concluded that the EVAL copolymer could be an ideal encapsulating material for drugs to treat chronic diseases.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Polymer Surface Interaction Studies · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (17)
Show source-provided references
1. Doxorubicin in sterically stabilized liposomes10.1038/380561a0 ↗
2. Y.W. Chien, Novel drug delivery systems, Marcel Dekker, New York, 1992.10.1201/b14196 ↗
3. Formulation of l-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release10.1016/S0168-3659(97)00196-X ↗
4. PDLLA microspheres containing steroids: spray-drying, o/w and w/o/w emulsifications as preparation methods10.3109/02652049809006848 ↗
5. Characterization of soluble, salt-loaded, degradable PLGA films and their release of tetracycline10.1002/(SICI)1097-4636(199807)41:1<18::AID-JBM3>3.0.CO;2-T ↗
6. Sea water demineralization by means of an osmotic membrane.10.1021/ba-1963-0038.ch009 ↗
7. S. Yamashita, S. Nagata Takakura K, US Patent 4, 134,837,197910.1295/koron.36.249 ↗
8. Effects of precipitation condition on the membrane morphology and permeation characteristics10.1016/S0376-7388(97)00281-0 ↗
9. Solute rejection of dextran by EVAL membranes with asymmetric and particulate morphologies10.1016/S0032-3861(97)00518-1 ↗
10. T.H. Young, W.Y. Chuang, C.W. Wei, C.Y. Tang, Investigation of the drug distribution and release characteristics from particulate membranes, J. Biomed. Mater. Res., 1999, submitted for publication.
11. Polymer conjugates: Pharmacokinetic considerations for design and development10.2165/00003088-199427040-00004 ↗
12. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models10.3109/10611869608996831 ↗
13. Partial synergism between dextran-conjugated doxorubicin and cancer drugs on the killing of multidrug resistant KB-V1 cells
14. Equilibrium phase behavior of the membrane forming water-DMSO-EVAL copolymer system10.1016/S0376-7388(96)00329-8 ↗
15. R.E. Kesting, Synthetic Polymeric Membranes, Wiley, New York, 1985
16. HPLC determination of a vincristine, doxorubicin, and ondansetron mixture in 0.9% sodium chloride injection10.1080/10826079408013772 ↗
17. Rapid colorimetric assay for cellular growth and survial: application to proliferation and cytotoxicity assays10.1016/0022-1759(83)90303-4 ↗